z-logo
Premium
Hyperthermic isolated regional perfusion with cisplatin in the local treatment of spontaneous canine osteosarcoma: Assessment of short‐term effects
Author(s) -
Van Ginkel Robert J.,
Hoekstra Harald J.,
Meutstege Freek J.,
Oosterhuis Jan W.,
Uges Donald R. A.,
Koops Heimen Schraffordt
Publication year - 1995
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930590307
Subject(s) - medicine , osteosarcoma , cisplatin , perfusion , term (time) , oncology , chemotherapy , pathology , physics , quantum mechanics
To increase the effect of cisplatin on locoregional osteosarcoma, the shortterm effect of hyperthermic isolated regional perfusion (HIRP) with cisplatin (30 mg/L extremity volume) was studied in 28 dogs with spontaneous osteogenic sarcoma, using clinical, radiological, and histological parameters. Thirty days postoperatively, mortality was 14.3%. Total platinum levels at the start of perfusion were 28.2 ± 14.3 mg/L. A significant improvement ( P < 0.001) in clinical score was observed in the overall group at 6 and 12 weeks after perfusion. The radiological parameter showed a stationary X‐ray 2 weeks after perfusion and an improved X‐ray 6 weeks after perfusion. Overall histological scores showed a moderate effect according to the Huvos classification. No additional therapeutic effect, according to the three parameters, could be demonstrated by increasing the perfusate temperature by 1°C. HIRP with cisplatin is feasible in the local treatment of spontaneous osteosarcoma in dogs with acceptable locoregional toxicity. However, the histological results were modest, with none of the dogs showing a complete response 6 weeks after perfusion. Therefore, the search for the ideal perfusion agent with substantial contribution to the limb‐sparing treatment in human osteosarcoma continues.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here